Positive safety of first cohort in Progenza stem cell trial
Filed with ASX · · 2 pages · English
Earlier from Cambium Bio
Later from Cambium Bio
- Appendix 4D and Half Yearly Report
- Response to 7.30 media commentary
- Enrolment complete and positive safety in Progenza trial
- ARC grant to progress stem cell research for chronic pain
- European patent to grant on stem cell secretions for acne
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio